The lysine 831 of vascular endothelial growth factor receptor 1 is a novel target of methylation by SMYD3

Cancer Research

Volumn 67, Issue 22, 2007, Pages 10759-10765

  Kunizaki, Masaki ^a,c   Hamamoto, Ryuji ^a   Silva, Fabio Pittella ^a   Yamaguchi, Kiyoshi ^a   Nagayasu, Takeshi ^c   Shibuya, Masabumi ^b   Nakamura, Yusuke ^a   Furukawa, Yoichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DNA DIRECTED RNA POLYMERASE; PROTEIN SMYD3; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 1;

ARTICLE; CANCER CELL; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; METHYLATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING;

CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; DNA METHYLATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; LYSINE; METHYLATION; MODELS, BIOLOGICAL; PHOSPHORYLATION; PLASMIDS; SERINE; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 36348996694     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-1132     Document Type: Article

References (36)

1. Kouzarides T. Chromatin modifications and their function. Cell 2007;128:693-705.
2. Strahl BD, Allis CD. The language of covalent histone modifications. Nature 2000;403:41-5.
3. Jenuwein T, Allis CD. Translating the histone code. Science 2001;293:1074-80.
4. Li B, Carey M, Workman JL. The role of chromatin during transcription. Cell 2007;128:707-19.
5. Zhang Y, Reinberg D. Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tails. Genes Dev 2001;15:2343-60.
6. Varambally S, Dhanasekaran SM, Zhou M, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002;419:624-9.
7. Hamamoto R, Furukawa Y, Morita M, et al. SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nat Cell Biol 2004;6:731-40.
8. Gibbons RJ. Histone modifying and chromatin remodelling enzymes in cancer and dysplastic syndromes. Hum Mol Genet 2005;14:R85-92.
9. Kouskouti A, Scheer E, Staub A, Tora L, Talianidis I. Gene-specific modulation of TAF10 function by SET9-mediated methylation. Mol Cell 2004;14:175-82.
10. Chuikov S, Kurash JK, Wilson JR, et al. Regulation of p53 activity through lysine methylation. Nature 2004;432:353-60.
11. Shibuya M, Yamaguchi S, Yamane A, et al. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene 1990;5:519-24.
12. Rahimi N. Vascular endothelial growth factor receptors: molecular mechanisms of activation and therapeutic potentials. Exp Eye Res 2006;83:1005-16.
13. Shibuya M. Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J Biochem Mol Biol 2006;39:469-78.
14. Sawano A, Takahashi T, Yamaguchi S, Aonuma M, Shibuya M. Flt-1 but not KDR/Flk-1 tyrosine kinase is a receptor for placenta growth factor, which is related to vascular endothelial growth factor. Cell Growth Differ 1996;7:213-21.
15. Hamamoto R, Silva FP, Tsuge M, et al. Enhanced SMYD3 expression is essential for the growth of breast cancer cells. Cancer Sci 2006;97:113-8.
16. Liu Q, Dreyfuss G. In vivo and in vitro arginine methylation of RNA-binding proteins. Mol Cell Biol 1995;15:2800-8.
17. Couture JF, Collazo E, Hauk G, Trievel RC. Structural basis for the methylation site specificity of SET7/9. Nat Struct Mol Biol 2006;13:140-6.
18. Volkel P, Angrand PO. The control of histone lysine methylation in epigenetic regulation. Biochimie 2007;89:1-20.
19. Huang J, Perez-Burgos L, Placek BJ, et al. Repression of p53 activity by Smyd2-mediated methylation. Nature 2006;444:629-32.
20. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling - in control of vascular function. Nat Rev 2006;7:359-71.
21. Porras-Yakushi TR, Whitelegge JP, Clarke S. Yeast ribosomal/cytochrome c SET-domain methyltransferase subfamily: identification of Rpl23ab methylation sites and recognition motifs. J Biol Chem 2007;282:12368-76.
22. Lesslie DP, Summy JM, Parikh NU, et al. Vascular endothelial growth factor receptor-1 mediates migration of human colorectal carcinoma cells by activation of Src family kinases. Br J Cancer 2006;94:1710-7.
23. Fan F, Wey JS, McCarty MF, et al. Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells. Oncogene 2005;24:2647-53.
24. Duff SE, Jeziorska M, Rosa DD, et al. Vascular endothelial growth factors and receptors in colorectal cancer: implications for anti-angiogenic therapy. Eur J Cancer 2006;42:112-7.
25. Andre T, Kotelevets L, Vaillant JC, et al. Vegf, Vegf-B, Vegf-C and their receptors KDR, FLT-1 and FLT-4 during the neoplastic progression of human colonic mucosa. Int J Cancer 2000;86:174-81.
26. Li YS, Kaneko M, Amatya VJ, Takeshima Y, Arihiro K, Inai K. Expression of vascular endothelial growth factor-C and its receptor in invasive micropapillary carcinoma of the breast. Pathol Int 2006;56:256-61.
27. Wu Y, Hooper AT, Zhong Z, et al. The vascular endothelial growth factor receptor (VEGFR-1) supports growth and survival of human breast carcinoma. Int J Cancer 2006;119:1519-29.
28. Chung GG, Yoon HH, Zerkowski MP, et al. Vascular endothelial growth factor, FLT-1, and FLK-1 analysis in a pancreatic cancer tissue microarray. Cancer 2006;106:1677-84.
29. Yang AD, Camp ER, Fan F, et al. Vascular endothelial growth factor receptor-1 activation mediates epithelial to mesenchymal transition in human pancreatic carcinoma cells. Cancer Res 2006;66:46-51.
30. Jackson MW, Roberts JS, Heckford SE, et al. A potential autocrine role for vascular endothelial growth factor in prostate cancer. Cancer Res 2002;62:854-9.
31. Jacobsen J, Grankvist K, Rasmuson T, Ljungberg B. Different isoform patterns for vascular endothelial growth factor between clear cell and papillary renal cell carcinoma. BJU Int 2006;97:1102-8.
32. Ljungberg BJ, Jacobsen J, Rudolfsson SH, Lindh G, Grankvist K, Rasmuson T. Different vascular endothelial growth factor (VEGF), VEGF-receptor 1 and -2 mRNA expression profiles between clear cell and papillary renal cell carcinoma. BJU Int 2006;98:661-7.
33. Wang FQ, So J, Reierstad S, Fishman DA. Vascular endothelial growth factor-regulated ovarian cancer invasion and migration involves expression and activation of matrix metalloproteinases. Int J Cancer 2006;118:879-88.
34. Chen H, Ye D, Xie X, Chen B, Lu W. VEGF, VEGFRs expressions and activated STATs in ovarian epithelial carcinoma. Gynecol Oncol 2004;94:630-5.
35. Soker S, Kaefer M, Johnson M, Klagsbrun M, Atala A, Freeman MR. Vascular endothelial growth factor-mediated autocrine stimulation of prostate tumor cells coincides with progression to a malignant phenotype. Am J Pathol 2001;159:651-9.
36. Wu W, Shu X, Hovsepyan H, Mosteller RD, Broek D. VEGF receptor expression and signaling in human bladder tumors. Oncogene 2003;22:3361-70.